The Latest Breaking News from MCK

As McKesson has outpaced the broader market over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects.

McKesson is expected to release its fiscal fourth-quarter earnings next month, and analysts project a double-digit profit growth.

Investors have been reminded that low growth is better than no growth; here are three dividend stocks that can provide shelter in the current storm

As Cencora has outperformed relative to the broader Nasdaq Composite over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects.

As recession indicators begin to flash, investors may turn to defensive plays for protection—these three stocks offer a compelling case for sturdiness.

As McKesson has outperformed the Dow Jones over the past year, analysts are bullish about the stock’s prospects.

Take a gander at these three stocks that are generating returns on invested capital (ROIC) that are among the best in the U.S. large-cap stock universe.

McKesson has underperformed relative to the S&P 500 Index over the past year, but Wall Street analysts remain bullish on its growth prospects.

With healthcare rapidly evolving through digital transformation, the demand for smarter, more efficient solutions is rising, and companies driving this shift are poised for significant upside. Therefore, investors might find opportunities in fundamentally strong healthcare IT stocks like Medtronic (MDT), McKesson Corp. (MCK), and Embecta (EMBC). Read more….

McKesson is expected to announce its third-quarter results next month, and analysts predict a single-digit growth in the company’s bottom-line figure.

Cencora has trailed the S&P 500 index over the past year, but analysts remain highly bullish about the stock’s prospects.